Equities

Zhejiang Hisun Pharmaceutical Co Ltd

600267:SHH

Zhejiang Hisun Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.07
  • Today's Change-0.07 / -0.98%
  • Shares traded4.82m
  • 1 Year change-35.08%
  • Beta1.0800
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold0
Sell1
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects Zhejiang Hisun Pharmaceutical Co., Ltd. share price to fall to 6.30 in the next year from the last price of 7.04.
High-10.5%6.30
Med-10.5%6.30
Low-10.5%6.30

Dividends

Historical dividend information is not available for Zhejiang Hisun Pharmaceutical Co Ltd.
Div growth (TTM)-100.00%
More ▼

Earnings history & estimates in CNY

On Aug 19, 2024, Zhejiang Hisun Pharmaceutical Co., Ltd. reported 2nd quarter 2024 earnings of 0.16 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 2nd quarter results by 20.00%.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate-54.40%
Zhejiang Hisun Pharmaceutical Co., Ltd. reported annual 2023 losses of -0.08 per share on Apr 29, 2024.
Average growth rate-97.14%
More ▼

Revenue history & estimates in CNY

Zhejiang Hisun Pharmaceutical Co., Ltd. had revenues for the full year 2023 of 10.37bn. Last year the company did not report any revenues.
Average growth rate+4.51%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.